Search
Searching Content indexed under Life Sciences, Biotechnology & Nanotechnology by WilmerHale ordered by Published Date Descending.
Links to Result pages
 
1 2  
>>Next
 
Title
Country
Organisation
Author
Date
1
What High Court Will Consider In Helsinn On-Sale Bar Case
The US Supreme Court may soon resolve an issue that has sparked much debate since the enactment of the Leahy-Smith America Invents Act—namely, whether under the AIA, an inventor's sale of an invention to a third party ...
United States
5 Dec 2018
2
Judgment Of The Court Of Justice Of The European Union Of July 25, 2018, In Case C-528/16 Confédération Paysanne And Others
On July 25, 2018, the Court of Justice (Court), sitting in a Grand Chamber, issued its judgment in Confédération paysanne and Others, by which it found that ...
European Union
7 Aug 2018
3
Brexit At Halfway: Pharma And Medical Devices
The object of this Alert is to highlight some practical implications of Brexit for the supply of pharmaceutical products and medical devices in the European Union (EU) and related action items...
United States
6 Apr 2018
4
Nations Press for International Restrictions to Govern Genetic Sequence Data
clash over access to and use of genetic sequence data (GSD) is currently brewing on several international fronts. To date, GSD has been routinely deposited in open-source databases such as GenBank of the National Center for Biotechnology Information ..
United States
19 May 2017
5
Finding A Way Through A Tight Deal Space
Last year's contentious U.S. presidential election is often blamed for the slowdown in dealmaking activity in the life sciences space.
United States
17 May 2017
6
Allergan And Editas Medicine Enter Into Strategic R&D Alliance
Editas Medicine, Inc., a leading genome editing company, and Allergan plc, a leading global pharmaceutical company, announced that Allergan's wholly-owned subsidiary—Allergan Pharmaceuticals International Limited—and Editas Medicine . . .
United States
20 Mar 2017
7
Park Square And Wilmerhale Release 17th Annual Technology And Life Sciences Compensation And Entrepreneurship Study
Growth rate in salaries for private company technology executives track higher than comparable life science leaders for the second year in a row.
United States
15 Feb 2017
8
Wilmerhale Reps Nantero In $21M Financing For Carbon Nanotube Computer Memory
Nantero Inc., the nanotechnology company developing next-generation memory using carbon nanotubes, announced the closing of more than $21 million financing round.
United States
21 Dec 2016
9
Regulation Of Synthetic Biology Under The Nagoya Protocol
This December, representatives from 196 nations will come to Mexico for the 13th meeting of the Convention on Biological Diversity (CBD).
United States
15 Nov 2016
10
Freedom To Utilize Genetic Resources? The Nagoya Protocol Two Years Later
Two years ago this month, the N agoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits from their Utilization to the Convention on Biological Diversity ("Protocol") entered into international force.
United States
2 Nov 2016
11
WilmerHale Advises Catabasis Pharmaceuticals In Closing Of $11.5M Offering Of Common Stock
Catabasis Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, announced the closing of an underwritten offering of 2,875,000 shares of its common stock...
United States
14 Oct 2016
12
The Nagoya Protocol Two Years Later
In December 2016, the Parties to the Protocol will meet in Mexico for their second biennial meeting to further implement the agreement.
Worldwide
14 Oct 2016
13
Doryx: Third Circuit Affirms Dismissal Of Product Hopping Claim
On September 28, 2016, in Mylan Pharmaceuticals Inc. v. Warner Chilcott Public Limited Co., the Third Circuit affirmed the lower court's grant of summary judgment against antitrust claims by generic manufacturer Mylan.
United States
30 Sep 2016
14
‘Follow-On Biologics': Ensuring Continued Innovation In The Biotechnology Industry
New protein products will likely need more market protection than what is provided to new drug products.
United States
12 Aug 2016
15
Trends In Inter Partes Review Of Life Sciences Patents
A statistical analysis of inter partes review proceedings before the Patent Trial and Appeal Board shows that the PTAB is not a ‘‘death squad'' for patents.
United States
11 Jul 2016
16
Stay Versus Stay: How Litigation Stays Pending IPRs Impact the 30-Month
Upon initiation of a patent infringement action between branded and generic pharmaceutical companies, the Hatch-Waxman Act (21 U.S.C. § 355(j)) provides for an automatic 30-month stay of
United States
30 Mar 2016
17
M&A: The Last Refuge For Biotechs Seeking Funding
These are tough times in the biotech and pharmaceutical industries: Funding is drying up, investors are fleeing the space, the IPO door is pretty firmly shut, valuations are dropping, activists are lurking and the headlines are anything but kind.
United States
15 Mar 2016
18
Inside Views: Learning From Ebola
In 1976, Yambuku village school headmaster Mabalo Lokela felt sick when he returned from a trip to northern Zaire near the Central African Republic border. He had a high fever, diarrhea, and bleeding.
United States
16 Jul 2015
19
Federal Circuit Patent Updates - May 2015
Federal Circuit Patent Updates - May 2015
United States
21 May 2015
20
Restrictions Governing International Trade In Genetic Resources Enter Into Force
On 12 October 2014, the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits from their Utilization (‘the Protocol’) entered into international force.
United States
5 May 2015
Links to Result pages
 
1 2  
>>Next